Microplate Dx Limited, an acclaimed spinout from the University of Strathclyde and a Deepbridge Life Sciences EIS portfolio company, has recently disclosed its participation as a speaker at The Times Life Sciences Summit, scheduled for March 20th in Aberdeen. Alongside Ben Carter, Investment Director and Head of Life Sciences at Deepbridge Capital, the company will contribute to the summit's discussions. 

Hosted in collaboration with Opportunity North East Limited, the summit aims to delve into the promising potential of the dynamic, innovative, and rapidly expanding life sciences sector. 

The United Kingdom's life sciences sector is at the forefront of addressing major global health challenges through scientific ingenuity, commercial innovation, and technological progress. This not only enhances lives but also drives robust economic growth. 

The North-East of Scotland stands out as a hub for clinical-stage biotech companies, further reinforced by the recent inauguration of the ONE BioHub innovation centre. This region is strategically positioned to harness the full potential of its life sciences sector in terms of health, well-being, and economic growth. The summit provides a unique opportunity to gain insights from Scottish entrepreneurs leading biotech, medtech, and healthtech companies such as Carcinotech, EpitogenX, Microplate Dx, TauRx, NovaBiotics, and Elasmogen.  

Attendees can explore cutting-edge approaches to drug discovery, including insights from artificial intelligence experts, and engage in discussions about the future of life sciences with prominent industry commentators, including the Bio Industry Association. 

Click here to find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).